SomnoMed (ASX:SOM) said its revenue for the quarter ended Dec. 31, 2024, grew 20% year-over-year to AU$28.5 million, according to a Friday Australian bourse filing.
Its revenue in the fiscal second quarter reported a jump in all geographies, with North America and Asia-Pacific achieving double-digit increases.
It updated its guidance for the fiscal year ending June 30, now expecting a revenue of about AU$105 million as well as earnings before interest, taxes, depreciation, and amortization of between AU$7 million to AU$9 million.
The firm's shares rose 10% in recent trading on Friday.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。